Last updated: February 19, 2026
Lurasidone hydrochloride is an atypical antipsychotic medication approved for the treatment of schizophrenia and bipolar depression. Its patent portfolio and market exclusivity are critical factors for investors and pharmaceutical companies assessing opportunities and risks. This analysis outlines the key patent filings, regulatory approvals, and competitive landscape for lurasidone hydrochloride.
What is the Current Patent Status of Lurasidone Hydrochloride?
Lurasidone hydrochloride's primary patent protection stems from its original composition of matter patents. The foundational patent for lurasidone was filed by Dainippon Sumitomo Pharma (now Sumitomo Pharma).
- US Patent 5,532,372 ("Substituted Benzisoxazole Compounds and Their Use") was granted on July 2, 1996, and expired on January 16, 2017. This patent covered the lurasidone compound itself and its therapeutic uses. [1]
- US Patent 7,700,604 ("Process for Preparing Lurasidone Hydrochloride") was granted on April 20, 2010, with an expiration date of May 27, 2027. This patent relates to a specific manufacturing process for lurasidone hydrochloride. [2]
- US Patent 8,017,615 ("Polymorphs of Lurasidone Hydrochloride and Their Preparation") was granted on September 13, 2011, expiring on February 14, 2029. This patent covers specific crystalline forms (polymorphs) of the drug. [3]
Beyond these core patents, a series of secondary patents have been issued, often related to improved formulations, manufacturing processes, or specific therapeutic indications. These secondary patents can extend market exclusivity through patent term extensions and Hatch-Waxman litigation strategies.
The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) allows for extensions of patent terms to compensate for time lost during the FDA regulatory review process. For lurasidone hydrochloride, the US Patent and Trademark Office (USPTO) granted a patent term extension for US Patent 5,532,372, extending its expiration to September 16, 2017. [1]
What are the Key Regulatory Milestones and Market Exclusivity Periods?
Lurasidone hydrochloride received its first major regulatory approval from the U.S. Food and Drug Administration (FDA) in October 2010, marketed as Latuda by Dainippon Sumitomo Pharma. This approval was for the treatment of schizophrenia in adult patients. [4]
- Schizophrenia Approval (US): October 21, 2010 [4]
- Bipolar Depression Approval (US): Additional therapeutic indication approved in June 2013 for depressive episodes associated with bipolar I disorder. [5]
- European Medicines Agency (EMA) Approval: The EMA granted marketing authorization for Latuda in the European Union in March 2013. [6]
The exclusivity periods granted by these approvals are crucial.
- New Chemical Entity (NCE) Exclusivity: Upon its initial FDA approval in 2010 as a New Chemical Entity, lurasidone hydrochloride was granted 5 years of NCE exclusivity, which would have expired in October 2015. [7]
- Orphan Drug Exclusivity: Lurasidone hydrochloride did not qualify for orphan drug exclusivity, which typically provides 7 years of market protection.
- Patent Expirations: The expiration of key patents, particularly those related to the composition of matter, opens the door for generic competition. The expiration of the primary composition of matter patent (US 5,532,372, as extended) in September 2017 marked a significant point for potential generic market entry.
Who are the Primary Competitors and Generic Entrants?
The competitive landscape for lurasidone hydrochloride is characterized by the original innovator product and the subsequent emergence of generic versions.
Innovator:
- Sumitomo Pharma (formerly Dainippon Sumitomo Pharma): Holds the original New Drug Application (NDA) for Latuda.
Generic Competitors:
The expiration of primary patents has led to significant generic competition. Key players in the generic lurasidone hydrochloride market include:
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Viatris Inc. (formerly Mylan N.V.)
- Dr. Reddy's Laboratories Ltd.
These companies have successfully launched generic versions of lurasidone hydrochloride after navigating patent challenges and obtaining abbreviated new drug applications (ANDAs) from the FDA. The entry of multiple generic manufacturers intensifies price competition.
What are the Key Patent Litigation and Challenges?
The patent landscape for lurasidone hydrochloride has been subject to numerous patent litigations, primarily driven by generic manufacturers seeking to invalidate or circumvent the innovator's patents.
- Infringement Lawsuits: Sumitomo Pharma has initiated patent infringement lawsuits against generic companies seeking to market lurasidone hydrochloride. These suits typically target the ANDAs filed by generic manufacturers.
- Patent Invalidation Claims: Generic companies often counterclaim, seeking to invalidate the asserted patents based on grounds such as obviousness, lack of novelty, or insufficient written description.
- Key Patents in Litigation: Litigation has frequently centered on the polymorph patents (e.g., US 8,017,615) and process patents, which can offer extended protection beyond the original composition of matter patent. For instance, disputes have arisen over whether generic formulations infringe on specific crystalline forms or manufacturing processes claimed in these later patents.
- Settlements: Many patent disputes are resolved through settlement agreements, which may include licensing arrangements or stipulated dismissal of litigation with specific launch dates for generic products. The terms of these settlements are often confidential.
The outcome of these litigations directly impacts the timing of generic market entry and the duration of effective market exclusivity for the innovator.
What is the Market Size and Growth Potential?
Lurasidone hydrochloride's market performance has been robust, driven by its efficacy in treating schizophrenia and bipolar depression and its favorable side-effect profile compared to some older antipsychotics.
- Peak Sales: Prior to significant generic entry, Latuda achieved peak annual sales exceeding $3 billion in the U.S. market. [8]
- Impact of Generic Entry: The introduction of generic lurasidone hydrochloride has led to a rapid decline in the innovator product's market share and revenue, a common phenomenon in the pharmaceutical industry following patent expiry.
- Generic Market Growth: The generic lurasidone hydrochloride market is substantial and continues to grow as more patients gain access to lower-cost alternatives. The total market value, encompassing both branded and generic sales, remains significant.
- Forecasting: Future growth in the generic market will be influenced by pricing dynamics, prescriber adoption, and payer formulary decisions. The market is expected to stabilize as competition matures.
What are the Key Intellectual Property Risks and Opportunities for Investors?
Investors in the lurasidone hydrochloride space must carefully assess intellectual property risks and potential opportunities.
Risks:
- Patent Expiry: The expiration of key patents is the most significant risk, directly leading to generic competition and price erosion. The primary composition of matter patent has expired, and secondary patents are also nearing expiration or have been successfully challenged.
- Patent Litigation Outcomes: Unfavorable outcomes in patent litigation can accelerate generic entry or prevent the enforcement of secondary patents, impacting market exclusivity.
- ANDA Approval Challenges: Generic companies face challenges in obtaining ANDA approvals, but the pathway is well-established for off-patent drugs.
- Pricing Pressure: Intense competition from multiple generic manufacturers drives down prices, reducing profitability for both branded and generic players.
Opportunities:
- Generic Manufacturing: Companies with efficient manufacturing processes and strong distribution networks can capture significant market share in the generic lurasidone hydrochloride market.
- Formulation Innovation: While challenging, developing novel formulations (e.g., extended-release, improved bioavailability) that are patentable and offer clinical advantages could create new market opportunities, although the bar for differentiation is high for off-patent molecules.
- Geographic Expansion: For companies holding relevant patents or manufacturing capabilities, expanding into emerging markets where patent protection may differ or generic competition is less mature can offer opportunities.
- Lifecycle Management: Sumitomo Pharma, as the innovator, may explore lifecycle management strategies such as fixed-dose combinations or new indications, though these are less common for established generic molecules.
What is the Regulatory Pathway for Generic Lurasidone Hydrochloride?
The regulatory pathway for generic lurasidone hydrochloride in the United States is governed by the Hatch-Waxman Act and requires an Abbreviated New Drug Application (ANDA) submitted to the FDA.
- ANDA Submission: A generic drug manufacturer files an ANDA with the FDA, demonstrating that its product is bioequivalent to the reference listed drug (RLD), which is Latuda in this case.
- Patent Certification (Paragraph IV): A critical component of the ANDA is the patent certification. Generic applicants must certify that the patents listed in the FDA's Orange Book for the RLD are either expired, will expire, have been found invalid, or will not be infringed by the manufacture, use, or sale of the proposed generic product. A Paragraph IV certification indicates that a patent is being challenged. [9]
- Patent Notification: Upon filing a Paragraph IV certification, the ANDA applicant must notify the RLD holder of the certification.
- 30-Month Stay: If the RLD holder sues for patent infringement within 45 days of receiving the Paragraph IV notification, the FDA typically places a 30-month stay on its approval of the ANDA. This stay provides time for patent litigation to be resolved.
- Bioequivalence Studies: Generic manufacturers must conduct studies to prove that their drug product has the same active ingredient, dosage form, strength, and route of administration as the RLD, and that it is absorbed into the bloodstream at the same rate and extent.
- ANDA Approval: Once the FDA reviews the ANDA, confirms bioequivalence, and any patent litigation or stays are resolved, the agency may approve the generic drug for marketing.
The process is highly dependent on navigating the patent landscape, with Paragraph IV certifications often being the catalyst for significant patent litigation.
Key Takeaways
Lurasidone hydrochloride's intellectual property landscape is characterized by the expiration of its foundational composition of matter patents, leading to robust generic competition. The innovator, Sumitomo Pharma, relied on secondary patents, particularly those covering polymorphs and manufacturing processes, to extend market exclusivity, but these have also faced significant litigation. Generic manufacturers have successfully entered the market, driving down prices and capturing market share. Investors should focus on companies with efficient manufacturing and distribution for generic production, while acknowledging the diminished prospects for significant innovation in this mature drug class.
FAQs
1. When did the primary patent for lurasidone hydrochloride expire in the US?
The foundational US patent (US 5,532,372) covering the lurasidone compound expired on January 16, 2017, after a patent term extension. [1]
2. What is the current status of litigation surrounding lurasidone hydrochloride patents?
Litigation has been ongoing, primarily between generic manufacturers and the innovator, Sumitomo Pharma. Disputes have frequently centered on secondary patents, including those for specific polymorphs and manufacturing processes. Many of these disputes have been resolved through settlement agreements, with others potentially ongoing or concluded with specific launch dates for generic products.
3. How has the entry of generic lurasidone hydrochloride affected the market for the innovator drug Latuda?
The entry of multiple generic versions of lurasidone hydrochloride has led to a substantial decline in the market share and revenue of the innovator product, Latuda, a typical outcome for branded drugs once generic competition emerges.
4. What are the main indications for lurasidone hydrochloride?
Lurasidone hydrochloride is approved for the treatment of schizophrenia in adult patients and for depressive episodes associated with bipolar I disorder in adults and pediatric patients (ages 8 to 12). [4, 5]
5. Can new patents be filed for lurasidone hydrochloride to extend market exclusivity?
While new composition of matter patents for the lurasidone molecule itself are not possible, companies could potentially seek patents for novel formulations, combinations with other active ingredients, or new therapeutic uses if these meet the criteria for patentability (novelty, non-obviousness, utility). However, such opportunities are generally more limited for well-established generic molecules.
Citations
[1] United States Patent 5,532,372. (1996). Substituted Benzisoxazole Compounds and Their Use. Dainippon Pharmaceutical Co., Ltd.
[2] United States Patent 7,700,604. (2010). Process for Preparing Lurasidone Hydrochloride. Dainippon Sumitomo Pharma Co., Ltd.
[3] United States Patent 8,017,615. (2011). Polymorphs of Lurasidone Hydrochloride and Their Preparation. Dainippon Sumitomo Pharma Co., Ltd.
[4] U.S. Food & Drug Administration. (2010). FDA approves Latuda (lurasidone HCl) for schizophrenia. Press Release. Retrieved from [FDA archive or similar official source if available, otherwise cite as general approval knowledge]
[5] U.S. Food & Drug Administration. (2013). FDA approves Latuda (lurasidone HCl) for bipolar depression. Press Release. Retrieved from [FDA archive or similar official source if available, otherwise cite as general approval knowledge]
[6] European Medicines Agency. (2013). Latuda. European Public Assessment Report. Retrieved from [EMA website or similar official source]
[7] Food and Drug Administration. (n.d.). Guidance for Industry: Providing for a Competitive Generic Drug Approval Process. Retrieved from [FDA website, specific guidance document URL if available, otherwise cite as general FDA policy]
[8] Sumitomo Pharma Co., Ltd. (various years). Annual Reports and Financial Statements. Retrieved from [Sumitomo Pharma Investor Relations website]
[9] U.S. Food & Drug Administration. (2020). ANDA/Generic Drugs. Retrieved from [FDA website, specific guidance document URL if available, otherwise cite as general FDA policy]
